Lab. of Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Istituto Nazionale Tumori Fond. G. Pascale, Naples, Italy.
Vaccine. 2011 Jul 12;29(31):4903-12. doi: 10.1016/j.vaccine.2011.05.005. Epub 2011 May 17.
Elicitation of a potent and broadly neutralizing antibody response is the main goal of an effective preventive HIV-1 vaccine. It has been shown by us and others that the expression of Env glycoproteins on the surface of particulate structures, such as Virus-Like Particles (VLPs), could be a more efficient strategy to deliver conformational epitopes to the immune system. To this aim, VLPs expressing native HIV Env gp140 or gp41 glycoproteins have been produced in insect cells using a baculovirus expression system and characterized for appropriate protein expression. VLP-bound HIV gp140 glycoprotein showed the appropriate expression and trimeric conformation. Immunogenicity studies have been performed in BALB/C mice by intra-peritoneal administration and sera from immunized mice have been tested in ELISA assays, for their reactivity with HIV specific antigens, as well as in ex vivo neutralization assay. Sera from immunized animals showed a high reactivity with individual HIV proteins expressed in VLPs. Results of TZM-bl based neutralization assay show that combined sera from animals independently immunized with gp140- or full-length-gp41-expressing VLPs have an additive/synergistic effect in the neutralization activity of HIV pseudoviruses. In conclusion, novel VLPs expressing different HIV Env glycoproteins with native trimeric conformation have been generated, showing the induction of effective antibody response with neutralization activity in TZM-bl neutralization assay. These results confirm the effectiveness of VLPs as presentation and delivery system for conformational proteins and show the improved neutralization activity upon the combination of anti-sera elicited by different HIV envelope antigens, suggesting the possibility of broadening the spectrum of viral epitopes targeted by immune response.
诱导有效的、广谱中和抗体反应是有效预防 HIV-1 疫苗的主要目标。我们和其他人已经证明,在颗粒状结构(如病毒样颗粒 (VLPs))表面表达 Env 糖蛋白可以更有效地将构象表位递送到免疫系统。为此,我们使用杆状病毒表达系统在昆虫细胞中表达了表达天然 HIV Env gp140 或 gp41 糖蛋白的 VLPs,并对其进行了适当的蛋白表达特征分析。VLP 结合的 HIV gp140 糖蛋白表现出适当的表达和三聚体构象。通过腹腔内给药在 BALB/C 小鼠中进行了免疫原性研究,并通过 ELISA 测定法检测了免疫小鼠的血清与 HIV 特异性抗原的反应性,以及在体外中和测定法中检测了血清的中和活性。免疫动物的血清与 VLPs 中表达的个体 HIV 蛋白具有高反应性。基于 TZM-bl 的中和测定法的结果表明,用 gp140 或全长 gp41 表达的 VLPs 分别免疫的动物的混合血清在中和 HIV 假病毒的活性方面具有相加/协同作用。总之,已经生成了具有天然三聚体构象的不同 HIV Env 糖蛋白的新型 VLPs,显示出在 TZM-bl 中和测定法中诱导有效的中和抗体反应的能力。这些结果证实了 VLPs 作为构象蛋白的呈递和递送系统的有效性,并显示出不同 HIV 包膜抗原诱导的抗血清组合的中和活性提高,表明有可能拓宽免疫反应靶向的病毒表位谱。